Price movement over the last 24 hours
iShares MSCI ACWI ETF vs Illumina, Inc. — how do they compare? iShares MSCI ACWI ETF trades at $155.53, while Illumina, Inc. trades at $186.52 (market cap $29.01B). Which is the better fit depends on your goals.
| ACWI | ILMN | |
|---|---|---|
52-Week High | $159.97 | $194.33 |
52-Week Low | $128.32 | $91.00 |
Market Cap | — | $29.01B |
Sector | — | Health |
Enterprise Value | — | $30.40B |
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
ILMN trades at $191.76, up 1.63% with bullish technical momentum and strong earnings beats. The stock shows robust profitability with 66.2% gross margins and 19.42% net income margins, though valuations remain elevated with a P/E of 34.31. Recent product launches like StrataMap Spatial and NovaSeq X demand drive growth, while Roche's new Axelios sequencer introduces competitive pressure. Cash flow improved to $291M in 2025 after prior volatility.
Outlook remains positive with analyst consensus at Buy (51%) and a $168.89 price target, though current price exceeds consensus. Key risks include rising debt-to-asset ratios (29.93% in 2025) and China market challenges. Upside depends on execution against new competition and sustaining high-margin sequencing growth.
Trailing returns across standard periods
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →